1 - 25 of 31 results for author:"Garrett M.D." in Literature citations
Results Customize
› Repeat search in UniProtKB (13)
| AT13148 is a novel, oral multi-AGC kinase inhibitor with potent pharmacodynamic and antitumor activity. Yap T.A., Walton M.I., Grimshaw K.M., Te Poele R.H., Eve P.D., Valenti M.R., de Haven Brandon A.K., Martins V., Zetterlund A., Heaton S.P. et al. Clin. Cancer Res. 18:3912-3923(2012) · Mapped (2) |
| The association of PI3 kinase signaling and chemoresistance in advanced ovarian cancer. Carden C.P., Stewart A., Thavasu P., Kipps E., Pope L., Crespo M., Miranda S., Attard G., Garrett M.D., Clarke P.A. et al. Mol. Cancer Ther. 11:1609-1617(2012) · Mapped (18) |
| Mechanism-based screen for G1/S checkpoint activators identifies a selective activator of EIF2AK3/PERK signalling. Stockwell S.R., Platt G., Barrie S.E., Zoumpoulidou G., Te Poele R.H., Aherne G.W., Wilson S.C., Sheldrake P., McDonald E., Venet M. et al. PLoS ONE 7:e28568-e28568(2012) · Mapped (6) |
| Structure-guided evolution of potent and selective CHK1 inhibitors through scaffold morphing. Reader J.C., Matthews T.P., Klair S., Cheung K.M., Scanlon J., Proisy N., Addison G., Ellard J., Piton N., Taylor S. et al. J. Med. Chem. 54:8328-8342(2011) · Mapped (1) |
| Structure-based design of potent and selective 2-(quinazolin-2-yl)phenol inhibitors of checkpoint kinase 2. Caldwell J.J., Welsh E.J., Matijssen C., Anderson V.E., Antoni L., Boxall K., Urban F., Hayes A., Raynaud F.I., Rigoreau L.J. et al. J. Med. Chem. 54:580-590(2011) · Mapped (1) |
| Design and evaluation of 3,6-di(hetero)aryl imidazo[1,2-a]pyrazines as inhibitors of checkpoint and other kinases. Matthews T.P., McHardy T., Klair S., Boxall K., Fisher M., Cherry M., Allen C.E., Addison G.J., Ellard J., Aherne G.W. et al. Bioorg. Med. Chem. Lett. 20:4045-4049(2010) · Mapped (1) |
| Discovery of 4-amino-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidine-4-carboxamides as selective, orally active inhibitors of protein kinase B (Akt). McHardy T., Caldwell J.J., Cheung K.M., Hunter L.J., Taylor K., Rowlands M., Ruddle R., Henley A., de Haven Brandon A., Valenti M. et al. J. Med. Chem. 53:2239-2249(2010) · Mapped (2) |
| Identification and characterisation of 2-aminopyridine inhibitors of checkpoint kinase 2. Hilton S., Naud S., Caldwell J.J., Boxall K., Burns S., Anderson V.E., Antoni L., Allen C.E., Pearl L.H., Oliver A.W. et al. Bioorg. Med. Chem. 18:707-718(2010) · Mapped (1) |
| Identification of inhibitors of checkpoint kinase 1 through template screening. Matthews T.P., Klair S., Burns S., Boxall K., Cherry M., Fisher M., Westwood I.M., Walton M.I., McHardy T., Cheung K.M. et al. J. Med. Chem. 52:4810-4819(2009) · Mapped (1) |
| TEAD1 and c-Cbl are novel prostate basal cell markers that correlate with poor clinical outcome in prostate cancer. Knight J.F., Shepherd C.J., Rizzo S., Brewer D., Jhavar S., Dodson A.R., Cooper C.S., Eeles R., Falconer A., Kovacs G. et al. Br. J. Cancer 99:1849-1858(2008) · Mapped (4) |
| Phosphorylation of cyclin dependent kinase 4 on tyrosine 17 is mediated by Src family kinases. Martin N.G., McAndrew P.C., Eve P.D., Garrett M.D. FEBS J. 275:3099-3109(2008) · UniProtKB (1) |
| Identification of 4-(4-aminopiperidin-1-yl)-7H-pyrrolo[2,3-d]pyrimidines as selective inhibitors of protein kinase B through fragment elaboration. Caldwell J.J., Davies T.G., Donald A., McHardy T., Rowlands M.G., Aherne G.W., Hunter L.K., Taylor K., Ruddle R., Raynaud F.I. et al. J. Med. Chem. 51:2147-2157(2008) · Mapped (2) |
| CHK2 kinase: cancer susceptibility and cancer therapy - two sides of the same coin? Antoni L., Sodha N., Collins I., Garrett M.D. Nat. Rev. Cancer 7:925-936(2007) · Mapped (9) |
| Rapid evolution of 6-phenylpurine inhibitors of protein kinase B through structure-based design. Donald A., McHardy T., Rowlands M.G., Hunter L.J., Davies T.G., Berdini V., Boyle R.G., Aherne G.W., Garrett M.D., Collins I. J. Med. Chem. 50:2289-2292(2007) · Mapped (2) |
| Identification of inhibitors of protein kinase B using fragment-based lead discovery. Saxty G., Woodhead S.J., Berdini V., Davies T.G., Verdonk M.L., Wyatt P.G., Boyle R.G., Barford D., Downham R., Garrett M.D. et al. J. Med. Chem. 50:2293-2296(2007) · Mapped (4) |
| A structural comparison of inhibitor binding to PKB, PKA and PKA-PKB chimera. Davies T.G., Verdonk M.L., Graham B., Saalau-Bethell S., Hamlett C.C., McHardy T., Collins I., Garrett M.D., Workman P., Woodhead S.J. et al. J. Mol. Biol. 367:882-894(2007) · UniProtKB (1) · Mapped (3) |
| Trans-activation of the DNA-damage signalling protein kinase Chk2 by T-loop exchange. Oliver A.W., Paul A., Boxall K.J., Barrie S.E., Aherne G.W., Garrett M.D., Mittnacht S., Pearl L.H. EMBO J. 25:3179-3190(2006) · UniProtKB (1) |
| Structure-based design of isoquinoline-5-sulfonamide inhibitors of protein kinase B. Collins I., Caldwell J., Fonseca T., Donald A., Bavetsias V., Hunter L.J., Garrett M.D., Rowlands M.G., Aherne G.W., Davies T.G. et al. Bioorg. Med. Chem. 14:1255-1273(2006) · Mapped (2) |
| The proto-oncoprotein SYT interacts with SYT-interacting protein/co-activator activator (SIP/CoAA), a human nuclear receptor co-activator with similarity to EWS and TLS/FUS family of proteins. Perani M., Antonson P., Hamoudi R., Ingram C.J., Cooper C.S., Garrett M.D., Goodwin G.H. J. Biol. Chem. 280:42863-42876(2005) · Mapped (11) |
| Regulation of NF-kappaB and p53 through activation of ATR and Chk1 by the ARF tumour suppressor. Rocha S., Garrett M.D., Campbell K.J., Schumm K., Perkins N.D. EMBO J. 24:1157-1169(2005) · UniProtKB (1) |
| Ecdysone-inducible expression of oncogenic Ha-Ras in NIH 3T3 cells leads to transient nuclear localization of activated extracellular signal-regulated kinase regulated by mitogen-activated protein kinase phosphatase-1. Plows D., Briassouli P., Owen C., Zoumpourlis V., Garrett M.D., Pintzas A. Biochem. J. 362:305-315(2002) · Mapped (8) |
| Cell cycle-regulated phosphorylation of p220(NPAT) by cyclin E/Cdk2 in Cajal bodies promotes histone gene transcription. Ma T., Van Tine B.A., Wei Y., Garrett M.D., Nelson D., Adams P.D., Wang J., Qin J., Chow L.T., Harper J.W. Genes Dev. 14:2298-2313(2000) · UniProtKB (2) |
| New functional activities for the p21 family of CDK inhibitors. LaBaer J., Garrett M.D., Stevenson L.F., Slingerland J.M., Sandhu C., Chou H.S., Fattaey A., Harlow E. Genes Dev. 11:847-862(1997) · UniProtKB (4) |
| Purification of GDP dissociation stimulator Dss4 from recombinant bacteria. Roberts D.M., Garrett M.D., Novick P.J. Meth. Enzymol. 257:84-92(1995) · Mapped (1) |
| Expression, purification, and assays of Gdi1p from recombinant Escherichia coli. Garrett M.D., Novick P.J. Meth. Enzymol. 257:232-240(1995) · Mapped (2) |